$0.50
1.01% today
Nasdaq, Sep 08, 04:21 pm CET
ISIN
US15673T1007
Symbol
IPSC

Century Therapeutics Inc Stock price

$0.50
-0.05 9.55% 1M
-0.10 16.94% 6M
-0.51 50.03% YTD
-0.94 64.95% 1Y
-9.98 95.18% 3Y
-22.33 97.79% 5Y
-22.33 97.79% 10Y
-22.33 97.79% 20Y
Nasdaq, Closing price Fri, Sep 05 2025
+0.03 5.41%
ISIN
US15673T1007
Symbol
IPSC
Industry

Key metrics

Basic
Market capitalization
$43.6m
Enterprise Value
$-112.2m
Net debt
positive
Cash
$155.8m
Shares outstanding
86.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.4 | 0.4
EV/Sales
negative | negative
EV/FCF
1.0
P/B
0.2
Financial Health
Equity Ratio
45.7%
Return on Equity
-78.4%
ROCE
-12.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$114.1m | $111.4m
EBITDA
$-19.5m | $-143.9m
EBIT
$-32.6m | $-25.6m
Net Income
$-23.3m | $-19.0m
Free Cash Flow
$-115.3m
Growth (TTM | estimate)
Revenue
5,494.6% | 1,589.7%
EBITDA
83.0% | -19.4%
EBIT
74.6% | 80.8%
Net Income
82.2% | 85.0%
Free Cash Flow
-12.0%
Margin (TTM | estimate)
Gross
-
EBITDA
-17.1% | -129.3%
EBIT
-28.5%
Net
-20.4% | -17.1%
Free Cash Flow
-101.0%
More
EPS
$-0.3
FCF per Share
$-1.3
Short interest
2.5%
Employees
145
Rev per Employee
$50.0k
Show more

Is Century Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,007 stocks worldwide.

Century Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Century Therapeutics Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Century Therapeutics Inc forecast:

Buy
90%
Hold
10%

Financial data from Century Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
114 114
5,495% 5,495%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 32 32
7% 7%
28%
- Research and Development Expense 110 110
15% 15%
96%
-20 -20
83% 83%
-17%
- Depreciation and Amortization 13 13
4% 4%
11%
EBIT (Operating Income) EBIT -33 -33
75% 75%
-29%
Net Profit -23 -23
82% 82%
-20%

In millions USD.

Don't miss a Thing! We will send you all news about Century Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Century Therapeutics Inc Stock News

Neutral
GlobeNewsWire
17 days ago
PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced that Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics, will share a company presentation at the H.C. Wainwr...
Neutral
GlobeNewsWire
25 days ago
Patient dosing ongoing in CALiPSO-1 trial; on track to report clinical data for CNTY-101 in patients with B-cell-mediated autoimmune diseases by year-end 2025 CNTY-308, a CAR-iT cell therapy functionally comparable to primary T cells, now in IND-enabling studies as a potential treatment for B-cell-mediated diseases; program expected to progress into the clinic in 2026 Dr. Brent Pfeiffenberger, ...
Neutral
GlobeNewsWire
3 months ago
PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is being held from June 1...
More Century Therapeutics Inc News

Company Profile

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It engages in harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

Head office United States
CEO Brent Pfeiffenberger
Employees 145
Founded 2018
Website www.centurytx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today